AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD-Related Sleep Di... (response of none on at least 6 of the ...)

AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD-Related Sleep Disturbances

Date:6/2/2009

response of "none" on at least 6 of the 7 days, allowing for one "mild" response. Relief of GERD-related sleep disturbance was defined as a "yes" response on no more than 2 of 7 consecutive days. Complete resolution of sleep disturbance was defined as 7 consecutive days of no trouble sleeping the previous night(1).

The primary objective was to demonstrate a difference in the relief of nighttime heartburn between NEXIUM 20 mg and placebo after four weeks of treatment. Secondary objectives included assessing the impact of treatment with NEXIUM versus placebo on GERD-related sleep disturbances(1).

About NEXIUM(R) (esomeprazole magnesium)

NEXIUM 40 mg and 20 mg daily are indicated for short-term treatment (4 to 8 weeks) in healing and symptomatic resolution of diagnostically confirmed erosive esophagitis (EE). NEXIUM 20 mg is indicated to maintain symptom resolution and healing of EE (controlled studies did not extend beyond 6 months), and for treatment of heartburn and other symptoms associated with GERD.

IMPORTANT SAFETY INFORMATION

NEXIUM is contraindicated in patients with known hypersensitivity to any component of the formulation or to substituted benzimidazoles.

The most frequently reported adverse events with NEXIUM include headache, diarrhea, and abdominal pain. Symptomatic response to therapy does not preclude the presence of gastric malignancy.

Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long-term with omeprazole, of which NEXIUM is an enantiomer.

As with all PPIs, patients treated concomitantly with warfarin may need to be monitored for increases in INR and prothrombin time. Like other proton pump inhibitors, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts, an
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine news :

1. AstraZeneca Leads Local Walking Movement
2. AstraZeneca Joins Local Walking Movement
3. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
4. Verus Pharmaceuticals Announces Divestiture of Pediatric Asthma Development Programs to AstraZeneca
5. AstraZeneca Recognized as One of Working Mothers 100 Best Companies for the Sixth Consecutive Year
6. AstraZeneca Launches New Program to Support Facilities that Connect People to Needed Medical Care and Prescription Assistance
7. NPS Sells Assets Related to mGluR Collaboration to AstraZeneca for $30 Million to Support Late-Stage Product Development
8. Everett-Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca
9. Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval
10. AstraZeneca Response to November 2, 2007 Ruling In Re: Pharmaceutical Industry Average Wholesale Price Litigation, MDL No. 1456, U.S. District Court, District of Massachusetts
11. AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R) (anastrozole) from the FDA

Post Your Comments:

(Date:12/15/2009)... Accelify is proud to announce the addition of David ... serve as Director of Development in the State of ... Advisors. ,, David Tokofsky was elected to ... in June 1995. As the Board Member for District ... from Northeast Los Angeles through East Los Angeles to ...

(Date:12/15/2009)... R.I., Dec. 15 Mergers and acquisitions ... expand their reach globally or complete a product ... the integration of safety programs. ,, A new ... Best Practices in a Hearing Conservation Program: US ... Airways and America West led the newly formed ...

(Date:12/15/2009)... 15 Reportlinker.com announces that ... available in its catalogue: ,, ... Therapeutics - Market Forecasts to 2015, ... Analysis ,, http://www.reportlinker.com/p0168100/The-Future-of-Autoimmune-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ... The author has released its latest ...

(Date:12/15/2009)... -- Research shows a direct correlation between effective ... building a culture of health improvement can result ... a new white paper from The Vitality Group, ... represents an ideal setting for the delivery of ... a corporate culture of health is a critical ...

(Date:12/15/2009)... -- The following is being released by the American ... Vera Rulon, MS, RHIT, CCS, FAHIMA ,, ... you joining us... ,, On behalf of the A-H-I-M-A ... our next chief executive officer, Doctor Alan Dowling... ,, ... search for someone who we knew could ...

[0] Accelify Announces the Addition of David Tokofsky to its National Board of Advisors [0] New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways [0] Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis [0] Optimizing Corporate Culture is Critical to the Success of Wellness Programs [0] Dowling Press Availability Tuesday, December 15, 2009 / 10:00 a.m. CST

... (Nasdaq: KERX ) today announced that on ... Stock Market ("Nasdaq") stating that the Company is no ... the Company to have a minimum of $2,500,000 in ... or $500,000 of net income from continuing operations for ...

... Pa., Nov. 21 Escalon Medical Corp. (Nasdaq: ... completed a $1,100,000 private placement of common stock and common ... Company sold 1,000,000 shares of common stock at $1.10 per ... additional 150,000 shares of common stock at an exercise price ...

... pioneer Compressus,Inc. today introduced the next generation ... software solutions with the release of the,MEDxConnect(TM) ... features a full,integration with GE Centricity PACS ... solutions package that increase the,efficiency and automation ...

... VICL ) today announced a strategic restructuring ... the company,s total workforce,and accelerated closure of a research ... employees and expects to reduce future,net losses and cash ... The restructuring is designed to ...

... wanted to get cosmetic surgery but either couldn,t afford it or ... the fear out of cosmetic surgery with a nonsurgical facelift that,s ... What more could you ask for? , ... Coral ...

... Web-based ,eValuator, tool developed to help businesses assess the health and value ... ... Bartlett Communications, an interactive design agency, has launched a new website tool ... with a resource to gauge the health and value of their website, ...

Other Medicine News:Health News:Keryx Biopharmaceuticals Receives Nasdaq Notification 2 Health News:Keryx Biopharmaceuticals Receives Nasdaq Notification 3 Health News:Escalon(R) Medical Corp. Completes $1.1 Million Private Equity Financing 2 Health News:Escalon(R) Medical Corp. Completes $1.1 Million Private Equity Financing 3 Health News:Compressus' Next Generation MEDxConnect(TM) Interoperability Solutions Feature GE Centricity and Philips iSite Integrations 2 Health News:Compressus' Next Generation MEDxConnect(TM) Interoperability Solutions Feature GE Centricity and Philips iSite Integrations 3 Health News:Compressus' Next Generation MEDxConnect(TM) Interoperability Solutions Feature GE Centricity and Philips iSite Integrations 4 Health News:Vical Announces Strategic Restructuring and Staff Reduction 2 Health News:Vical Announces Strategic Restructuring and Staff Reduction 3 Health News:Miami's Soluna MD Introduces New Cosmetic Surgery Facelift Technique With Permalift 2 Health News:Miami's Soluna MD Introduces New Cosmetic Surgery Facelift Technique With Permalift 3 Health News:Miami's Soluna MD Introduces New Cosmetic Surgery Facelift Technique With Permalift 4 Health News:Bartlett Communications Launches Free Website Evaluation Tool for Small to Mid-Sized Businesses 2

Keryx Biopharmaceuticals Receives Nasdaq Notification Escalon(R) Medical Corp. Completes $1.1 Million Private Equity Financing Compressus' Next Generation MEDxConnect(TM) Interoperability Solutions Feature GE Centricity and Philips iSite Integrations Vical Announces Strategic Restructuring and Staff Reduction Miami's Soluna MD Introduces New Cosmetic Surgery Facelift Technique With Permalift Bartlett Communications Launches Free Website Evaluation Tool for Small to Mid-Sized Businesses

(Date:12/15/2009)... Iowa, Dec. 15 Vivakor, Inc. ... Vivakor,s divisions have reported strong performance in ... research and development with divisional spokes developing ... R&D Product Pipeline strategy is anchored to ... From idea inception, Vivakor,s R&D efforts target ...

(Date:12/15/2009)... Calif., Dec. 15 Genomic Health, Inc. (Nasdaq: ... studies on its Onco type DX® breast cancer ... to predict the likelihood of chemotherapy benefit and recurrence ... were presented at the 32nd Annual CTRC-AACR San Antonio ... in San Antonio, TX. ,, "The breadth of data ...

(Date:12/15/2009)... Mass., Dec. 15 Arlington Medical Resources ... Staphylococcus aureus (MRSA) is the most concerning ... regard to their treatment of skin and skin ... among the top factors that influences European physician ... infections. Other key factors that drive prescribing include ...

Breaking Medicine Technology:Vivakor Divisions Continue to Demonstrate Independent Growth 2 Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 2 Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 3 Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 4 Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 5 Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 6 Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 7 A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections 2 A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections 3 American Regent Expands Voluntary Recall to Include All Lots of Ketorolac Tromethamine Injection USP 15 mg mL 3B 1mL Single Dose Vials 5964 1 American Regent Expands Voluntary Recall to Include All Lots of Ketorolac Tromethamine Injection USP 15 mg mL 3B 1mL Single Dose Vials 5964 2 Study 3A Lap band surgery effective for morbidly obese children 60640 1 Renowned cardiovascular researcher to receive Taylor Prize 60638 1

[0] Vivakor Divisions Continue to Demonstrate Independent Growth [0] Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations [0] A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections

... Three Years from Lilly Foundation Could ,Fill a ... Major Gap, in Diabetes Science -, ... Eli Lilly and Company announced today that they are,joining together to ... into drugs and therapies to cure diabetes and its,complications by developing ...

... the currently approved therapy ... INDIANAPOLIS, Nov. 14 New data, ... Medicine, showed that in patients with,glucocorticoid-induced osteoporosis ... increased lumbar spine bone mineral,density (BMD) from ...

Other Medicine Technology:JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers 2 JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers 3 JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers 4 FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis 2 FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis 3 FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis 4 FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis 5 FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis 6

JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis

The clarity and performance of glass with shatterproof safety of plastic....

Hemato-clad Hematocrit Tubes combine the precision of glass with the safety provided by a Mylar® overwrap. Now you can give your laboratory staff safety with no compromise in accuracy....

... technology uses advanced spectral analysis techniques ... images and provide detailed information on ... plaques. The colorized VH images show ... dense calcium, and necrotic core. VH ...

... Medtronic is changing the way clinicians and ... Medtronic CareLink Monitor and a standard phone ... from their home or while traveling. 1 ... the ability to review device data when ...

Medicine Products:

Fisherbrand Plastic Microhematocrit Tubes Hemato-Clad Mylar® Wrapped Hematocrit Tubes VH™ IVUS Imaging System CareLink® Network

AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD-Related Sleep Di...(response of none on at least 6 of the ...),Health